Imagion Biosystems Ltd
ASX:IBX
Imagion Biosystems Ltd
Research & Development
Imagion Biosystems Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Imagion Biosystems Ltd
ASX:IBX
|
Research & Development
-AU$679.8k
|
CAGR 3-Years
41%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cochlear Ltd
ASX:COH
|
Research & Development
-AU$299.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Research & Development
-AU$5.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-15%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Research & Development
-AU$3.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Imagion Biosystems Ltd
Glance View
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The firm's principal activities include nanotechnology, biotechnology, cancer diagnostics and medical imaging using superparamagnetic relaxometry. Its MagSense technology is a functional imaging method for detecting cancers and other critical diseases. MagSense instrument uses sensitive magnetic sensors to detect the tiny bio-safe nanoparticles. MagSense nanoparticles bound to cancer cells act like a magnetic beacon to identify the presence of a tumour. MagSense nanoparticles are supplied as an injectable solution and formulated to provide delivery to specific types of cancer cells. Its PrecisionMRX nanoparticles are developed for magnetic relaxometry and other biomedical applications. The company serves a range of applications, including detecting cancer, monitoring therapy and detecting other diseases. Its MagSense HER2 imaging agent is under phase I clinical study.
See Also
What is Imagion Biosystems Ltd's Research & Development?
Research & Development
-679.8k
AUD
Based on the financial report for Jun 30, 2025, Imagion Biosystems Ltd's Research & Development amounts to -679.8k AUD.
What is Imagion Biosystems Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
23%
Over the last year, the Research & Development growth was 80%. The average annual Research & Development growth rates for Imagion Biosystems Ltd have been 41% over the past three years , 23% over the past five years .
